IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: To be Assigned	
Stephen H. BARTELMEZ, et al.	Art Unit: To be Assigned	
Application Serial No. To be Assigned	Parent Serial No. 09/490,520	
Filed: Herewith	Parent Filed: January 25, 2000	
For: ANTI-TRANSFORMING FROWTH) FACTOR BETA (TGF-BETA))) Attorney's Docket No. 37932-0002 D1	
TREATED STEM CELL) COMPOSITION AND METHOD)	Customer No. 25213	

EXPRESS MAIL LABEL NO. EV 346 723 811 US

Date Mailed: JULY 9, 2003

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Applicants wish to bring to the attention of the Patent Office the references listed on the attached Form PTO-1449 and request that they be considered by the Examiner. Each of the references listed on the attached Form PTO-1449, was previously cited by or submitted to the PTO in prior Application Serial No. <u>09/490,520</u>, filed <u>January 25, 2000</u>, therefore copies are not enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3), therefore no fee is due. The Commissioner is authorized to charge any fees which may be required under 37 CFR §1.16 or §1.17, to Deposit Account No. <u>08-1641</u>, referencing Attorney's Docket No. <u>37932-0002 D1</u>.

Respectfully submitted,

Date: July 9, 2003

Anna L. Barry (Reg. No. 51,436

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Direct Dial: (650) 324-6951 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

Form PTO-1449		Attorney's Docket No. 37932-	Attorney's Docket No. 37932-0002 D1 Application Serial No. To be Assigned						
INFO	RMATIO	ON DISCLOS	SURE STATEMENT	Applicant(s) Stephe	en H. BARTEL				
(use several sheets if necessary)			if necessary)	Filing Date: July 9, 2003		t Unit: To be Assigned			
a Maria	1.2	10		U.S. PATENT DOCUMENTS	Helion Holonia	A art Mead		Marine Committee	
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)		
	1.*	10/1991	5,061,620	Tsukamoto, et al.					
	2.*	9/1999	5,958,774	Klein, et al.					
tell will	ren (Sinc			OREIGN PATENT DOCUMENTS					
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Translation		
Initials	No.						YES	NO	
	3.*	9/1994	WO 94/18991	PCT					
	4.*	6/1996	WO 96/19567	PCT					
				OTHER DOCUMENTS					
			(includin	g author, title, date, pertinent pages, e	etc.)				
Examiner	Ref.	Title							
Initials	No.								
	5.*	142(5):153	6-1541 (1989)	ntibodies Recognizing Transforming		·			
	6.*	Fortunel, N. el al., "Release from Quiescence of Primitive Human Hematopoietic Stem/Progenitor Cells by Blocking Their Cell-Surface TGF-Beta Type II Receptor in a Short-Term In Vitro Assay", Stem Cells - 18(2):102-111 (2002)							
	7.*	Hatzfeld, A., et al., "Increased Stable Retroviral Gene Transfer in Early Hematopoietic Progenitors Released from Quiescence", <i>Human Gene Therapy</i> – 7:207-213 (1996)							
	8.*		, M. et al., "Growth-Regulatory Factors for Normal, Premalignant, and Malignant Human Cells In Vitro", <i>Adv. in</i> r Research - <u>54</u> :213-234 (1990)						
	9.*							od	
	10.*							(1990)	
	11.*								
	12.*	Sitnicka, E., et al., "Transforming Growth Factor β ₁ Directly and Reversibly Inhibits the Initial Cell Divisions of Long- Term Repopulating Hematopoietic Stem Cells", <i>Blood</i> – <u>88</u> (1):82-88 (1996)							
	13.*	Soma, T., et al., "Maintenance of Murine Long-Term Repopulating Stem Cells in Ex Vivo Culture is Affected by							
	'''		Modulation of Transforming Growth Factor-β but not Macrophage Inflammatory Protein-1α Activities," Blood –						
			1-4567 (1996)	, у			,		
	14.*	Wang, X.F	el al., "Expression Clo	oning and Characterization of the TGF					
	15.*			celeration and Stem Cell Expansion ir					
			Hemat – <u>22</u> :1051-1057 (
	16.*			Antibody to TGF-Beta Overcomes No. m 16(c), Abstract No. M342 (1992)	ormal Growth C	ontrols in Lon	g-Term Bon	9	
*****	17.*			β Activity During Retroviral Transduc	tion Improves N	furine Hemato	poietic Proc	enitor	
			_	sfer Efficiency", Gene Therapy - 5:12	•			,	
	 				(1000)				

EX/	٩M	IN	ER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the r ference number, a copy is not pr vided because the reference was previously cited by or submitted to th PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).